RU2606128C2 - Соединения для применения в лечении мукозита - Google Patents

Соединения для применения в лечении мукозита Download PDF

Info

Publication number
RU2606128C2
RU2606128C2 RU2013155678A RU2013155678A RU2606128C2 RU 2606128 C2 RU2606128 C2 RU 2606128C2 RU 2013155678 A RU2013155678 A RU 2013155678A RU 2013155678 A RU2013155678 A RU 2013155678A RU 2606128 C2 RU2606128 C2 RU 2606128C2
Authority
RU
Russia
Prior art keywords
independently
alkyl
group
independently represents
groups
Prior art date
Application number
RU2013155678A
Other languages
English (en)
Russian (ru)
Other versions
RU2013155678A (ru
Inventor
Ричард У. СКОТТ
Божена КОРЧАК
Original Assignee
Селлсьютикс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селлсьютикс Корпорейшн filed Critical Селлсьютикс Корпорейшн
Publication of RU2013155678A publication Critical patent/RU2013155678A/ru
Application granted granted Critical
Publication of RU2606128C2 publication Critical patent/RU2606128C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
RU2013155678A 2011-05-16 2012-05-15 Соединения для применения в лечении мукозита RU2606128C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486455P 2011-05-16 2011-05-16
US61/486,455 2011-05-16
PCT/US2012/037895 WO2012158672A2 (en) 2011-05-16 2012-05-15 Compounds for use in treatment of mucositis

Publications (2)

Publication Number Publication Date
RU2013155678A RU2013155678A (ru) 2015-06-27
RU2606128C2 true RU2606128C2 (ru) 2017-01-10

Family

ID=47175383

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013155678A RU2606128C2 (ru) 2011-05-16 2012-05-15 Соединения для применения в лечении мукозита

Country Status (14)

Country Link
US (6) US8802683B2 (enExample)
EP (1) EP2709619B1 (enExample)
JP (1) JP5833745B2 (enExample)
KR (1) KR102012164B1 (enExample)
CN (1) CN103957710B (enExample)
AU (1) AU2012255935B2 (enExample)
CA (1) CA2836099C (enExample)
DK (1) DK2709619T3 (enExample)
IL (1) IL229381B (enExample)
MX (1) MX2013013330A (enExample)
RU (1) RU2606128C2 (enExample)
TW (1) TWI520951B (enExample)
WO (1) WO2012158672A2 (enExample)
ZA (1) ZA201308541B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
WO2012158672A2 (en) * 2011-05-16 2012-11-22 Polymedix, Inc. Compounds for use in treatment of mucositis
US9783490B2 (en) * 2012-12-18 2017-10-10 The Secretary Of State For Health Antimicrobial compounds, their synthesis and applications thereof
JP6474736B2 (ja) * 2013-02-15 2019-02-27 テヒーニィシエ ウニヴェルジテート ベルリン アルビシジン誘導体、その使用および合成
WO2014150338A1 (en) 2013-03-15 2014-09-25 Genzyme Corporation Amine functional polyamides
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2021248008A1 (en) 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
CN117858717A (zh) 2021-08-30 2024-04-09 联合化学实验室有限公司 用于治疗炎症性疾病的蛋白质组合物
CN114890982A (zh) * 2022-05-16 2022-08-12 内蒙古大学 一种季铵盐修饰的二苯并噻吩亚砜衍生物的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025326A (en) * 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
WO2004082634A2 (en) * 2003-03-17 2004-09-30 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
WO2006122162A2 (en) * 2005-05-10 2006-11-16 The University Of Chicago Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
WO2008083256A2 (en) * 2006-12-29 2008-07-10 Polymedix, Inc. Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof
RU2540077C2 (ru) * 2008-10-27 2015-01-27 Селлсьютикс Корпорейшн Синтетические миметики иммунной защиты и их применение

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
DE69220679T2 (de) 1992-01-23 1997-10-23 Morinaga Milk Industry Co. Ltd., Tokio/Tokyo Antibakterielles mittel und behandlung von gegenständen mit diesem
US5994306A (en) * 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins
JP3090125B2 (ja) 1997-08-26 2000-09-18 千寿製薬株式会社 ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
ATE239003T1 (de) 1998-08-20 2003-05-15 Univ North Carolina Dibenzothiophene derivate und ihre verwendung
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6440964B1 (en) 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
DK1339414T3 (da) 2000-11-08 2010-04-19 Fxs Ventures Llc L-histidin i ophthalmiske opløsninger
CA2434693A1 (en) * 2001-01-18 2002-10-17 Genzyme Corporation Ionene polymers and their use as antimicrobial agents
EP1372674B1 (en) 2001-03-08 2011-05-25 The Trustees of The University of Pennsylvania Facially amphiphilic polymers as anti-infective agents
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
AR034372A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US6841578B2 (en) * 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
EP1535235A1 (en) 2002-05-28 2005-06-01 The Trustees of The University of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
JP2005529604A (ja) 2002-06-13 2005-10-06 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 粗粒度モデルを用いる生体膜をシミュレートするための方法、システム、およびコンピュータプログラム製品
AU2003291087A1 (en) * 2002-11-19 2004-06-15 Genzyme Corporation Ionene oligomers and polymers
AU2003249114A1 (en) 2003-03-20 2004-10-11 Shiseido International France Cosmetic composition
US20040202687A1 (en) 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050065091A1 (en) 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
EP2468711A3 (en) 2004-01-23 2012-09-19 The Trustees Of The University Of Pennsylvania Facially amphiphilic polyaryl and polarylalkynyl polymers and oligomers and uses thereof
KR101172722B1 (ko) 2004-06-15 2012-08-16 폴리메딕스, 인코포레이티드 다가양이온성 화합물 및 이의 용도
US20060024264A1 (en) 2004-07-23 2006-02-02 Kenichi Kuroda Antimicrobial copolymers and uses thereof
EP2301349A2 (en) 2005-02-25 2011-03-30 The Trustees of The University of Pennsylvania Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
ATE485819T1 (de) * 2005-03-24 2010-11-15 Rottapharm Spa Benzamidin derivative zur behandlung und vorbeugung von mucositis
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2008137978A (ja) 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
US8796275B2 (en) * 2008-07-28 2014-08-05 The Trustees Of The University Of Pennsylvania Anti-malarial compounds
US20100144761A1 (en) * 2008-12-10 2010-06-10 Polymedix, Inc. Antimicrobial Molecules For Treating Multi-Drug Resistant And Extensively Drug Resistant Strains Of Mycobacterium
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
US20110178104A1 (en) * 2010-01-07 2011-07-21 Polymedix Inc. Anti-Heparin Compounds
TW201208677A (en) * 2010-08-21 2012-03-01 Polymedix Inc Facially amphiphilic compounds, compositions, and uses thereof in treating cancer
WO2012158672A2 (en) * 2011-05-16 2012-11-22 Polymedix, Inc. Compounds for use in treatment of mucositis
AU2012352621A1 (en) * 2011-12-13 2014-07-24 Cellceutix Corporation Cyclic compounds and methods of making and using the same
SG11201404165RA (en) * 2012-01-18 2014-10-30 Cellceutix Corp Compounds and methods for treating candidiasis and aspergillus infections
US20140308317A1 (en) * 2012-12-10 2014-10-16 Cellceutix Corporation Polymeric Compounds And Methods Of Making And Using The Same
US20140171438A1 (en) * 2012-12-10 2014-06-19 Cellceutix Corporation Hybrid Compounds And Methods Of Making And Using The Same
NZ713946A (en) * 2013-05-28 2019-09-27 Morphochem Aktiengesellschaft Fuer Komb Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025326A (en) * 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
WO2004082634A2 (en) * 2003-03-17 2004-09-30 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
WO2006122162A2 (en) * 2005-05-10 2006-11-16 The University Of Chicago Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
WO2008083256A2 (en) * 2006-12-29 2008-07-10 Polymedix, Inc. Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof
RU2540077C2 (ru) * 2008-10-27 2015-01-27 Селлсьютикс Корпорейшн Синтетические миметики иммунной защиты и их применение

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DONNELLY ET AL.: "Antimicrobial therapy to prevent or treat oral mucositis", LANCET INFECTIOUS DISEASES, ELSEVIER LTD, US, 2003, vol. 3, no. 7, pages 405-412. *
DONNELLY ET AL.: "Antimicrobial therapy to prevent or treat oral mucositis", LANCET INFECTIOUS DISEASES, ELSEVIER LTD, US, 2003, vol. 3, no. 7, pages 405-412. LOURY D J ET AL.: "Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters", ORAL SURGERY, ORAL MEDICINE, ORAL PATHOLOGY, ORAL RADIOLOGY AND ENDODONTICS, MOSBY-YEAR BOOK, ST. LOUIS, MO, US, 1999, vol. 87, no. 5, pages 544-551. *
LOURY D J ET AL.: "Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters", ORAL SURGERY, ORAL MEDICINE, ORAL PATHOLOGY, ORAL RADIOLOGY AND ENDODONTICS, MOSBY-YEAR BOOK, ST. LOUIS, MO, US, 1999, vol. 87, no. 5, pages 544-551. *

Also Published As

Publication number Publication date
US20180064664A1 (en) 2018-03-08
RU2013155678A (ru) 2015-06-27
EP2709619A2 (en) 2014-03-26
CA2836099C (en) 2020-06-16
US20120295922A1 (en) 2012-11-22
US9457027B2 (en) 2016-10-04
WO2012158672A3 (en) 2014-05-08
JP5833745B2 (ja) 2015-12-16
KR20140078582A (ko) 2014-06-25
CN103957710B (zh) 2016-04-20
CN103957710A (zh) 2014-07-30
TWI520951B (zh) 2016-02-11
US9795575B2 (en) 2017-10-24
IL229381B (en) 2018-04-30
US8802683B2 (en) 2014-08-12
US10603294B2 (en) 2020-03-31
US10206894B2 (en) 2019-02-19
WO2012158672A2 (en) 2012-11-22
AU2012255935B2 (en) 2016-06-23
CA2836099A1 (en) 2012-11-22
TW201247654A (en) 2012-12-01
JP2014516033A (ja) 2014-07-07
US20140364364A1 (en) 2014-12-11
NZ618249A (en) 2016-03-31
IL229381A0 (en) 2014-01-30
EP2709619A4 (en) 2015-04-22
US20170224640A1 (en) 2017-08-10
ZA201308541B (en) 2015-04-29
US20190282521A1 (en) 2019-09-19
EP2709619B1 (en) 2017-10-11
US9155738B2 (en) 2015-10-13
US20160213668A1 (en) 2016-07-28
MX2013013330A (es) 2014-07-09
KR102012164B1 (ko) 2019-08-20
DK2709619T3 (en) 2018-01-15

Similar Documents

Publication Publication Date Title
RU2606128C2 (ru) Соединения для применения в лечении мукозита
AU2012255935A1 (en) Compounds for use in treatment of mucositis
US20190084940A1 (en) Benzamide derivatives
CN105682655B (zh) 抗微生物化合物
EA037517B1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
US20110178104A1 (en) Anti-Heparin Compounds
WO2019205687A1 (zh) 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
AU2011334592C1 (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
WO1989005637A1 (en) Improving toxicity profiles in chemotherapy
JP2013530244A (ja) 免疫調節の方法
CN112204025B (zh) 用于治疗疼痛的化合物，包含其的组合物以及使用其的方法
NZ618249B2 (en) Compounds for use in treatment of mucositis

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner